title: Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics.
abstract: The antipsychotic drugs (APDs) are fundamental tools in current psychiatric practice. A new generation of agents, the atypical APDs, represents an important progress in the treatment of psychotic disorders. Unfortunately, some of them induce excessive body weight gain (BWG), obesity, hyperglycemia and dyslipidemia in the following order: clozapine approximately equal to olanzapine > quetiapine > risperidone > ziprasidone = aripiprazole. Appetite stimulation is probably the main mechanism of BWG and this is strongly correlated with the APD affinity for H1 (histaminergic) and alpha1 (adrenergic) receptors. A composed ratio of the APD affinity for diverse neurotransmitters involved in food intake (FI) regulation correlates with BWG as well. Endocrine/metabolic mechanisms, such as the activation of the hypothalamus-pituitary-adrenal axis, changes in insulin sensitivity (by conventional and atypical agents), hyperprolactinemia and gonadal dysfunction (by conventional APDs and risperidone) may also be involved. Importantly, patients with schizophrenia may have a genetically-based predisposition to appetite dysregulation, insulin resistance and endocrine imbalance involving gonadal steroids. Excessive BWG must be prevented or attenuated by proper drug selection, combining or switching agents, nutritional assistance and physical exercise. Amantadine. metformin and reboxetine proved to significantly lessen APD-induced BWG. Notwithstanding this, novel strategies are necessary to treat this side effect in a clinical population particularly prone to poor compliance and under a high risk of negative drug interaction.
authors.affiliation: Department of Physiology, P.O. Box 93, Los Andes University Medical School, Mérida, 5101-A, Venezuela. trinbap@yahoo.com
authors.forename: T
authors.initials: T
authors.lastname: Baptista
authors.forename: J
authors.initials: J
authors.lastname: Zárate
authors.forename: R
authors.initials: R
authors.lastname: Joober
authors.forename: C
authors.initials: C
authors.lastname: Colasante
authors.forename: S
authors.initials: S
authors.lastname: Beaulieu
authors.forename: X
authors.initials: X
authors.lastname: Páez
authors.forename: L
authors.initials: L
authors.lastname: Hernández
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000378:metabolism / Q000627:therapeutic use; D001066:Appetite / Q000187:drug effects; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008659:Metabolic Diseases / Q000139:chemically induced / Q000378:metabolism / Q000503:physiopathology; D009765:Obesity / Q000209:etiology; D015430:Weight Gain / Q000187:drug effects*
chemical_list: D014150:Antipsychotic Agents